Biopharma dealmakers reflect on last year's shifts in the market, as they gear up for another 'active' year ahead
While 2021 was another big year for biopharma R&D — with the number of IPOs and biotech VC funding eclipsing last year’s impressive amounts — we also saw a few shifts in the market.
First off, biopharma M&A was down 11% from 2020, with a notable increase in deals around CDMOs and the services space. And VCs have also shown a growing interest in platform and earlier-stage programs, according to numbers compiled by DealForma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.